Qiagen N.v. · NYSE:QGEN
Qiagen — Investor Presentation (May 2022)
111 slides from Qiagen's investor presentation, May 16, 2022
Slide 1: Investor resource book Second quarter 2022
Making improvements in life possible Investor resource book Second quarter 2022 Sample to Insight
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. S
Slide 3: Table of Contents
Table of Contents About QIAGEN 4 QIAGEN at a glance 6 Global presence 14 Business areas 15 Strategy 18 Debt information 24 Capital allocation 25 Why invest 26 Product portfolios 27 Sample technologies 29 Diagnostic solutions 34 PCR / Nucleic acid amplification 49 Genomics / NGS 57 Sustainability 65
Slide 4: We help advance science and improve outcomes
We help advance science and improve outcomes Our Mission Enabling access to valuable insights from molecular research to clinical healthcare Our Vision Making improvements in life possible Q2 2022 Investor Resource Book 4
Slide 5: Helping customers to make advances in science and patient care
Helping customers to make advances in science and patient care QIAGEN QIAGEN enters the QIAGEN launches pioneers the molecular diagnostic the first liquid first plasmid market with a test to biopsy-based prep kit, cutting test to screen for companion extraction time cervical cancer diagnostic for Fi
Slide 6: QIAGEN at a glance
QIAGEN at a glance Our products support scientists and clinicians to advance scientific discovery and improve patient outcomes A global company with scale Balanced customer markets $2.2 bn ~50% ~50% >500,000 (2021 sales) Molecular customers Life Diagnostics Sciences worldwide Diverse global presence
Slide 7: There is an unprecedented need for molecular research and testing
There is an unprecedented need for molecular research and testing to tackle the health challenges of our time Our knowledge about Tuberculosis is still Cancer remains a Infectious diseases the building blocks of one of the world’s leading cause of have been – and life – DNA, RNA and most significant
Slide 8: Our products are found in laboratories worldwide
Our products are found in laboratories worldwide - from young scientists to Nobel laureates Q2 2022 Investor Resource Book 8
Slide 9: We help over 500,000 customers unlock molecular insights
We help over 500,000 customers unlock molecular insights that address healthcare challenges. That’s how we help make improvements in life possible. Q2 2022 Investor Resource Book 9
Slide 10: QIAGEN provides solutions to uncover molecular insights from Sample to Insight
QIAGEN provides solutions to uncover molecular insights – faster, better and more efficiently – from Sample to Insight Biological Sample to Valuable sample Insight solutions molecular insights • Sample Technologies • Advancing knowledge about the building • Assay Technologies blocks of life – DNA, R
Slide 11: We are known for the highest quality products
We are known for the highest quality products Q2 2022 Investor Resource Book 11
Slide 12: We are COVID relevant – but not COVID dependent
We are COVID relevant – but not COVID dependent >750 million COVID-19 tests in 2021 relied on QIAGEN products Testing Surveillance • RNA sample preparation • Immune level testing • PCR testing solutions • NGS variant monitoring • OEM components • Wastewater testing for other suppliers Q2 2022 Invest
Slide 13: Ready to serve public health needs across the globe
And we are ready to serve public health needs across the globe Determined to leave no country behind with a portfolio of dedicated tests and strategic partnerships TB testing for low-resource Testing for high-risk human Sample technologies high-burden regions with papillomavirus (HPV) using supporti
Slide 14: Global presence with a focus on attractive markets
Global presence with a focus on the most attractive developed and emerging markets Our global and regional headquarters Venlo Netherlands 35 subsidiaries Global HQ Germantown Maryland Americas HQ Distribution Hilden partners in over Germany in over 25 EMEA HQ Shanghai China Asia-Pacific HQ 60 countr
Slide 15: Life Sciences: Enabling the advancement of science
Life Sciences: Enabling the advancement of science QIAGEN value ~$5 billion 2021 sales Academia addressable market of ~$1.1 billion Recognized innovator supporting breakthrough science Pharma Ability to translate ~5-6% CER innovations into market growth (excl.COVID) commercial products Applied Testi
Slide 16: Molecular Diagnostics: Improving outcomes for patients
Molecular Diagnostics: Improving outcomes for patients QIAGEN value ~$6 billion 2021 sales of ~$1.1 billion addressable market Focused on high-growth, high-demand opportunities Strong automation portfolio with multi-year assay menu ~6-7% CER expansion underway Clinical market growth (excl.COVID) hea
Slide 17: Bioinformatics: Genomic data analysis and interpretation
Bioinformatics: Offering unique genomic data analysis and interpretation capabilities QIAGEN value Clinical Healthcare ~$620 million 2021 sales: ~$89 million addressable market Academia Industry leader in commercial bioinformatics solutions Pharma Offering solutions in ~15% CER combination with the
Slide 18: Our Strategy: Focus on areas to build and maintain leading positions
Our Strategy: Focus on areas to build and maintain leading positions Expanding on solid leadership Early commercialization phases with strong growth potential Nr. 1 in QuantiFERON for QIAstat-Dx for NeuMoDx for Leading the way Sample technologies immune response near-patient syndromic mid- to high-t
Slide 19: Five pillars of growth: Advancing key drivers
Five pillars of growth: Advancing key drivers to capture the largest opportunities Targeting >$6 billion of our >$11 billion total addressable market Sample technologies QuantiFERON QIAstat-Dx NeuMoDx QIAcuity • Leading reputation, • Fully automated • Sample prep in <1 • Faster time to result • Rapi
Slide 20: Five pillars of growth: Expected trends in 2022 and beyond
Five pillars of growth: Expected trends in 2022 and beyond 2021 Cumulative 2022 sales goals placements sales goals Mid-term goals (CER) (As of Jan 2022) (CER) QIAsymphony >3,000 Sustainable low- to mid- Sample technologies >$750 m QIAcube >13,000 >$750 m EZ1 and EZ2 >4,800 single-digit CER growth Su
Slide 21: FY 2021: Solid growth trends beyond COVID in all product groups
FY 2021: Solid growth trends beyond COVID in all product groups Non-COVID / COVID split By product group (In $ millions at actual rates) (In $ millions at actual rates) +19% CER +19% CER $2,252 $2,252 $1,870 $1,870 851 Sample technologies +4% CER 1,547 Non-COVID 804 product groups 1,252 Diagnostic +
Slide 22: FY 2021: Investing in the business while building value
FY 2021: Investing in the business while building value Adj. operating income Adjusted EPS Operating cash flow (In $ millions) (In $ per share) (In $ millions) Targeted investments into key drivers $639 ~65% of R&D spending focused on five pillars of growth 190 $458 $755 $2.65 Disciplined operating
Slide 23: Outlook: Q2 and FY 2022
Outlook: Q2 and FY 2022 Q2 2022 outlook FY 2022 outlook > $510 million CER ≥ $2.12 billion CER Net sales Adverse FX impact of ~ -4-5 p.p Adverse FX impact of ~ -4 p.p. Anticipated currency impact (Prior year: $567.2 m) (Prior year: $2,251.7 m) Non-COVID product groups Double-digit CER growth ≥ $0.46
Slide 24: Maintaining financial flexibility with appropriate leverage
Maintaining financial flexibility with appropriate leverage and cost-efficient debt structures Structure as of December 31, 2020 Maturities of debt instruments (In $ millions) $2.1 billion Cash and U.S. Private Placement Schuldschein Convertible Bonds short-term Convertible 117 investments Bonds 644
Slide 25: Supporting growth while increasing returns to shareholders
Supporting growth while increasing returns to shareholders Healthy cash flow trends Invest in the business 500 1.8 1.5x Fuel sustainable and profitable 1.6x 0.9x 1.5x 1.6 growth, especially in the five pillars 1.4x 400 1.4 458 449 1.2 Enhance value with M&A 300 359 1.0 Ongoing disciplined approach w
Slide 26: Why invest in QIAGEN
Why invest in QIAGEN: Strong de-risked investment case with compelling differentiation Highly recurring Broad geographic Diversified customer revenues reach base Sales driven by steady customer Robust structures securing access to Well-balanced sales split between shipments of high margin consumable
Slide 27: QIAGEN product portfolios
QIAGEN product portfolios Sample to Insight
Slide 28: Reporting sales in product groups
Reporting sales in product groups QIAGEN Five pillars of growth Sample QIAcuity product groups technologies(1) digital PCR(3) QIAstat-Dx NeuMoDx QuantiFERON Sample technologies(1) Consumables and instruments used in sample collection, stabilization, storage, purification and quality control includin
Slide 29: Sample technologies
Sample technologies Customers Sample collection, stabilization Manual sample preparation and storage solutions Life Sciences Academic Pharma Applied testing Molecular Diagnostics Automated sample preparation Quality control instruments Q2 2022 Investor Resource Book 29
Slide 30: The first step in virtually any molecular biology laboratory process
The first step in virtually any Sample technologies molecular biology laboratory process QIAGEN holds leading products in the vast majority of applications mRNA microRNA Total RNA from FFPE tissue Gel extraction Post-reaction cleanup ~70-75% Total RNA from whole (i.e. PCR, enzyme of QIAGEN sample bl
Slide 31: Our Sample technologies are the foundation of QIAGEN
Our Sample technologies are the foundation of QIAGEN Sample technologies A portfolio that has grown to address the complete spectrum of processing biological samples Selected biological samples Applications Tissue Stool Input demands Processing Target analytes Cloning qPCR / dPCR Cells Saliva Low /
Slide 32: Building on Sample Technologies solid leadership
Building on Sample Technologies solid leadership Sample technologies Upgrading key automation platforms Comprehensive consumables portfolio QIAcube Connect EZ2 Connect QIAsymphony Boost Launched 2019 Launched 2021 In development Over 300 kits • Any sample format Add photo • Any analyte for QS (DNA,
Slide 33: SPOTLIGHT: QIAsymphony
SPOTLIGHT: QIAsymphony – Sample technologies Flagship platform for sample processing Off-the-shelf solutions and customizable protocols to fit wide range of laboratory needs Front-end automation solution for molecular testing Regionalization strategy • US: Focus on sample technologies • Rest-of-worl
Slide 34: Diagnostic solutions
Diagnostic solutions Customers Immune Response Infectious diseases Molecular Diagnostics Women’s Health Oncology and Precision Medicine Q2 2022 Investor Resource Book 34
Slide 35: Immune Response: Best-in-class IGRA test for latent tuberculosis
Immune Response: Best-in-class IGRA Diagnostic solutions test for latent tuburculosis What is QuantiFERON? Latent TB testing market QuantiFERON-TB Gold Plus (QFT-Plus) is a simple blood test that aids in the detection >$1 QIAGEN of Mycobacterium tuberculosis, the bacteria which causes tuberculosis (
Slide 36: A growing market demand for modern latent TB testing
A growing market demand Diagnostic solutions for modern latent TB testing What is the difference between latent TB ~70 million latent TB tests per year across the world and active TB? Latent TB infection (LTBI) can persist for weeks, months or years North before developing into active disease. Altho
Slide 37: QuantiFERON offers fully automated workflows
QuantiFERON offers fully automated workflows Diagnostic solutions for low and high throughput testing Enabling hands-free processing QuantiFERON differentiation of QFT-TB Gold Plus Full automation capability DiaSorin Strong Highly specific best-in-class LIASON XS & XL market No inter-reader variabil
Slide 38: QuantiFERON Lyme: Combination of tests
QuantiFERON Lyme: Combination of Diagnostic solutions tests allowing a new level of detection CE-IVD test launched in 2021 Rising occurrence of Lyme disease 40,000 Confirmed cases Potential testing market Europe ~35,000 per year ~12-14 million tests per year U.S. ~30,000 per year ~5 million tests pe
Slide 39: Infectious diseases: New generation of PCR technology
Infectious diseases: New generation Diagnostic solutions of PCR technology for urgent needs Core / Hospital laboratories Near-patient clinical laboratories Hospital and Community hospitals and reference lab networks reference lab “outreach” centers Requirements: Requirements: Market opportunity Mark
Slide 40: QIAstat-Dx: Capturing opportunities in syndromic testing
QIAstat-Dx: Capturing Diagnostic solutions opportunities in the rapidly growing market of syndromic testing What is syndromic testing? Syndromic testing is a new approach to molecular diagnostic testing which uses a single test to look for multiple viral, bacterial or fungal infections. Sets of comm
Slide 41: QIAstat-Dx: Reliable, fast and cost-effective diagnosis
QIAstat-Dx: Reliable, fast and cost-effective Diagnostic solutions diagnosis of complex syndromes Unrivaled ease-of-use Liquid / solid sample input Dry swab sample input Self- contained cartridge Real-time PCR reaction chambers Analytical modules Operational module • Small footprint with More than a
Slide 42: QIAstat-Dx: Expanding menu in U.S. and Europe
QIAstat-Dx: Expanding menu Diagnostic solutions in U.S. and Europe Broadening the addressable market with QIAstat-Dx Rise Growing test menu CE-IVD FDA Gastrointestinal Small hospitals Medium-sized hospitals National reference labs, Public health labs Regional reference labs Large IDNs Respiratory Si
Slide 43: QIAstat-Dx: Novel syndromic testing system
QIAstat-Dx: Diagnostic solutions Novel syndromic testing system delivering unique value QIAstat-Dx (4 scalable slots QIAstat-Dx - Rise Biofire FilmArray Biofire Torch Luminex ePlex Genmark Verigene used for (1 slot) (12 slots) (12 slots) (1 slot) comparison) Throughput (in 8 hours) 28 56 9 108 60 4
Slide 44: NeuMoDx: Bringing simplicity to integrated PCR testing
NeuMoDx: Bringing simplicity of clinical Diagnostic solutions chemistry to integrated PCR testing New generation of integrated PCR NeuMoDx differentiation • Easier: Three-step workflow process Two scalable platforms: 96 and 288 • Faster: First results in ~1 hour Fully acquired in September 2020 • Mo
Slide 45: NeuMoDx: Unique integrated PCR platform in >$3 billion market
NeuMoDx: A unique integrated PCR testing Diagnostic solutions platform in >$3 billion market opportunity Roche Cobas Hologic Hologic 6800 Roche Cobas Beckman Veris NeuMoDx 288 NeuMoDx 96 Abott Alinity M Panther Panther Fusion (+ Omni LDT 8800 (Discontinued) channel) Volume in '00,000s cm3 38 16 18 2
Slide 46: Oncology and Precision Medicine: Partner of choice
Oncology and Precision Medicine: Diagnostic solutions QIAGEN as a partner of choice CDx and LDT Market >25 >$1.1 billion annually ~15% CAGR Currently mostly LDT’s pharma partnerships Day One Lab Readiness program Program designed to further accelerate the access of cancer patients to QIAGEN’s compan
Slide 47: Oncology and Precision Medicine: Partner of choice
Oncology and Precision Medicine: Diagnostic solutions QIAGEN as a partner of choice QIAGEN molecular diagnostic development 2021 sales: ~$80 million 26 IVD development programs either in pre-clinical or clinical phase • ~50% Pharma co- Offering both development revenues PCR and NGS technologies 20 C
Slide 48: Women's Health: Prenatal testing and STD detection
Women’s Health: Prenatal Diagnostic solutions testing and detection of sexually transmitted diseases Cervical cancer screening Digene – Comprehensive range of human papillomavirus DNA test Maternal / Fetal testing AmniSure – For the detection of PAMG-1 in amniotic fluid of pregnant women PartoSure –
Slide 49: PCR / Nucleic Acid amplification
PCR / Nucleic Acid amplification Customers Digital PCR - QIAcuity PCR reagents and instrumentation Life Sciences Academic Pharma Applied testing Customized arrays Q2 2022 Investor Resource Book 49
Slide 50: PCR: One of the most widely used tools in molecular biology
PCR: One of the most widely used PCR / Nucleic acid amplification tools in molecular biology What is polymerase chain reaction (PCR)? The process of replicating a specific DNA fragment though a series of thermal cycling to generate thousands to millions of copies. Unlimited customization of arrays t
Slide 51: Digital PCR: A new level of precision and sensitivity
Digital PCR: PCR / Nucleic acid amplification A new level of precision and sensitivity What is digital PCR? Digital PCR is a highly accurate approach for nucleic acid detection and quantification. The basic principle is the same as other PCR technologies Replicating a specific DNA fragment though a
Slide 52: Digital PCR: The latest generation of PCR technology
Digital PCR: The latest generation of PCR technology PCR / Nucleic acid amplification 1st generation 2nd generation 3rd generation Conventional PCR Quantitative RT-PCR (qPCR) Digital PCR (dPCR) Qualitative Relative quantification Absolute quantification Technically simple High accuracy, sensitivity
Slide 53: Leveraging novel technology with QIAcuity digital PCR
Leveraging novel technology with QIAcuity digital PCR PCR / Nucleic acid amplification Enabling access to the Easy-to-use comprehensive PCR market system vs. competition QIAcuity Differentiated nanoplate system QIAcuity One QIAcuity Four QIAcuity Eight Q2 2022 Investor Resource Book 53
Slide 54: QIAcuity digital PCR continuing to expand applications
Five pillars: QIAcuity digital PCR continuing PCR / Nucleic acid amplification to expand applications QIAcuity dPCR differentiation Easier Fully automated workflow in one compact instrument Faster Over twice as fast as droplet digital PCR; results in under 2 hours More versatile Scalable throughput
Slide 55: PCR enzymes, reagents, and arrays for research workflows
PCR enzymes, reagents, and arrays PCR / Nucleic acid amplification for research workflows QuantiNova: Automatable, ultrafast kits QuantiNova: Automatable, ultrafast kits with in-process controlled safety measures with in-process controlled safety measures • PCR or 1-step & 2-step RT-PCR • Expert-des
Slide 56: Customized arrays: GeneGlobe design and analysis portal
Customized arrays: GeneGlobe design PCR / Nucleic acid amplification and analysis portal for biological content A world of genes, pathways and biological targets Find NGS, PCR and functional analysis assays in the relevant scientific context. Design custom products with full flexibility on target re
Slide 57: Genomics / NGS
Genomics / NGS Customers Universal NGS consumables Illumina collaboration NGS assays Life Sciences Academic Pharma Applied testing Molecular Diagnostics Bioinformatics solutions Q2 2022 Investor Resource Book 57
Slide 58: Universal NGS: QIAseq solutions
Universal NGS: QIAseq solutions providing Genomics / NGS high-performance chemistry Target enrichment and streamlined library preparation leveraging leading sample preparation and bioinformatics QIAGEN NGS differentiation NGS research market Superior technology performance for target enrichment >$80
Slide 59: Partnership to accelerate use of NGS in clinical decision-making
Partnership to accelerate use of NGS Genomics / NGS in clinical decision-making QIAGEN to develop and market NGS IVD kits (including CDx assays) for use on Illumina systems • Integrated with QIAGEN sample technologies, NGS IVD kits and bioinformatics solutions for “Sample to Insight” experience NGS
Slide 60: QIAGEN Digital Insights: Turning sequencing data into actionable information
QIAGEN Digital Insights: Turning Genomics / NGS sequencing data into clinically actionable information Bioinformatics [baɪ.oʊˌɪnfərˈmætɪks] is an interdisciplinary field that develops methods and software tools for understanding biological data. As an interdisciplinary field of science, bioinformati
Slide 61: The partner of choice for actionable insights
The partner of choice for actionable insights Genomics / NGS from molecular and real-world data Multi-year partnership examples Preferred vendor for Deliver custom NGS Molecular oncology and Genomics England to patient data oncogenetic screening analyze 5 million interpretation for data in Japan’s l
Slide 62: Discovery Insights: Serving the research community
Discovery Insights: Serving the research community Genomics / NGS Example: Analyzing gene expression data from Sample to Insight Biological Freedom sample of Choice Sample Data to Information to Knowledge to data information knowledge to insight NGS library prep Normalization and QC Data Integration
Slide 63: Clinical Insights: Serving the diagnostic laboratories
Clinical Insights: Serving the diagnostic laboratories Genomics / NGS Software platform for scalable, standardized and reproducible variant interpretation VCF FASTQ Variant Variant alignment Variant assessment, Sequencing Final report and quality triage classification and control interpretation ONCO
Slide 64: Customer quote: insights point to a possible therapeutic target
“The insights we gained through QIAGEN’s analysis point the way to a possible therapeutic target for disease intervention.” DR. MATTHEW DODSON Post-Doctoral Research Associate, Department of Pharmacology and Toxicology, University of Arizona Because of QIAGEN our customers are making improvements in
Slide 65: Sustainability at QIAGEN
Sustainability at QIAGEN Sample to Insight
Slide 66: Committed to building a sustainable business
Committed to building a sustainable business We have set ambitious goals to contribute to a more sustainable future – never compromising on our high quality standards By 2050: Goal: 35% 100% Carbon neutral women in leadership Suppliers committed in 2022 to sustainable 2030 interim goal: 40% 2021 lev
Slide 67: Environmental protection is an issue of continued concern
Environmental protection is an issue of continued and committed concern for QIAGEN Eco-friendly transportation Conversion of air freight to sea freight saving ~1.164 tons/year of CO₂ since 2018 Reduction of Scope 1 & 2 CO₂ emissions by 9.1% in 2020 Reduction of business travel CO₂ emissions by 81.1%
Slide 68: Integrating sustainability throughout the value chain
Integrating sustainability throughout the value chain Examples of sustainability in product design • Avoiding materials that cause a lot of damage when they are mined, cannot be recycled or do not decompose • Improving repairability, longevity, and allowing for reuse • Designing products to use less
Slide 69: QIAwave: New eco-friendly versions of best-selling kits
QIAwave: New eco-friendly versions of best-selling kits QIAwave RNA Mini Kit / QIAwave DNA Blood & Tissue Kit / QIAwave Plasmid Miniprep Kit Waste tubes made from 100% Up to 63% post-consumer recycled plastic less plastic 86% reduction in concentrated buffers plastic materials Up to 42% less cardboa
Slide 70: Plastic footprint reduction
Plastic footprint reduction Reduce Reduced the thickness of blister film in packaging equating to a 2800 kg annual reduction Reduced the number of gel packs used equating a 33.4 ton annual reduction Replace Replaced packaging with sustainable material for cold shipments in North America and Canada –
Slide 71: Conducting business in a responsible way
Conducting business in a responsible way through ethical foundations Respecting human rights and legally compliant business behavior Supply Chain Conflict minerals As part of our supplier selection Certain minerals (known as “conflict process, we assess the suppliers’ minerals”) have been linked wit
Slide 72: Deepening commitment to diversity and inclusion
Deepening commitment to diversity and inclusion Diverse teams strengthen our organization through the variety of ideas, perspectives and approaches Executive Council Diversity and Ongoing strategic on Equal Inclusion initiative to increase Opportunity (ECEO) Ambassador Program gender diversity Creat
Slide 73: Passionate QIAGENers around the world
>6,000 People from all functions working together to passionate QIAGENers achieve our vision: around the world are Making improvements employed by QIAGEN in life possible Q2 2022 Investor Resource Book 73
Slide 74: We have a culture of empowerment driven by achieving targets
We have a culture of empowerment driven by achieving targets Decentralized decision-making • Giving teams at all levels greater influence • Bringing decisions closer to customers Ambitious but realistic targets • Appropriately balance opportunity and risk • Training teams on PREmortem analysis A cul
Slide 75: QIAGEN operates under a two-tier corporate structure
QIAGEN operates under a two-tier corporate structure QIAGEN has established an Executive Committee (EC) – which comprises the CEO, the CFO and certain experienced leaders. Under leadership of the CEO, the members of the Executive Committee share powers and responsibilities for operational management
Slide 76: Executive Committee / Managing Board
Executive Committee / Managing Board Thierry Bernard Roland Sackers Chief Executive Officer Chief Financial Officer Joined QIAGEN in February 2015 to lead QIAGEN’s Joined QIAGEN in 1999 as Vice President Finance and growing presence in Molecular Diagnostics, the application has been Chief Financial
Slide 77: Executive Committee
Executive Committee Dr. Thomas Schweins Thierry Bernard Dr. Jonathan Sheldon Sr. Vice President, Head of Life Sr. Vice President, Head Sr. Vice President, Digital Science Business Area of Molecular Dx Bus. Area Insights Business Area Joined QIAGEN in 2004 as Vice President Corporate Joined QIAGEN in
Slide 78: Executive Committee
Executive Committee Stephany Foster Antonio M. Santos Sr. Vice President, Head of HR Sr. Vice President, Head of Global Operations Joined QIAGEN in 2005 as Head of Global Internal Antonio M. Santos joined QIAGEN in April 2022 as Audit and was most recently Vice President, Head of Senior Vice Preside
Slide 79: Supervisory Board
Supervisory Board Lawrence A. Rosen Dr. Metin Colpan Chair of the Supervisory Board Supervisory Director Joined the Supervisory Board in 2013 and was He is a co-founder of QIAGEN, its first Chief Executive appointed Chair in 2020. He is Chair of the Audit Officer and a Managing Director from 1985 to
Slide 80: Supervisory Board
Supervisory Board Thomas Ebeling Dr. Toralf Haag Prof. Dr. Ross L. Levine Supervisory Director Supervisory Director Supervisory Director Joined the Supervisory Board in February 2021. Mr. Dr. Toralf Haag joined the Supervisory Board and the Joined the Supervisory Board and its Science and Ebeling ha
Slide 81: Supervisory Board
Supervisory Board Prof. Dr. Elaine Mardis Elisabeth E. Tallett Supervisory Director Supervisory Director Joined the Supervisory Board in 2014. She is a member of Joined the Supervisory Board, as well as the Audit the Science and Technology Committee and the Committee and Compensation Committee, in 2
Slide 82: Scientific Advisory Board
Scientific Advisory Board Chair Members Dr. Peter Kaspar Dr. Neville Sanjana Prof. Dr. Ross Levine Leadership positions at Core Faculty Member at the Roche Diagnostics and New York Genome Center bioMérieux during career in and Assistant Professor at diagnostics, Life Sciences New York University and
Slide 83: Q1 2022 results
Q1 2022 results Exceeded outlook with strong performance across non-COVID and COVID product groups
Slide 84: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be, deemed to be forward looking statements within the meaning of Section 27A of the U.S.
Slide 85: Q1 2022: Strong focus on delivering and exceeding targets
Q1 2022: Strong focus on delivering and exceeding targets Net sales (CER) Q1 2022: +15% vs. ≥ 7% outlook +14% non-COVID products +18% COVID products Adjusted EPS (CER) Q1 2022: $0.83 vs. ≥ $0.72 outlook CER - Constant Exchange Rates. Refer to appendix for reconciliation of reported to adjusted figur
Slide 86: Q1 2022: Execution of strategy driving sustainable growth
Q1 2022: Execution of strategy driving sustainable growth High-performing Expanding Dynamic operating 2022 outlook updated core business portfolio value cash flow for strong Q1 +14% CER growth in Record Q1 2022 instruments Operating cash flow +61% Sales: >$2.12 billion CER non-COVID product placemen
Slide 87: Q1 2022: Solid non-COVID sales in all product groups
Q1 2022: Solid non-COVID sales in all product groups Non-COVID / COVID split By product group (In $ millions at actual rates) (In $ millions at actual rates) +15% CER +15% CER $628 $628 $567 $567 265 Sample +22% CER technologies 400 Non-COVID 227 product groups 364 +14% CER Diagnostic +21% CER 174 s
Slide 88: Q1 2022: EMEA and APAC leading sales growth
Q1 2022: EMEA and APAC leading sales growth Americas • U.S. and Brazil: Delivered single-digit CER growth Europe / Middle East / Africa • Germany, Spain and Netherlands: Solid double-digit CER gains EMEA APAC / Japan • UK: Single-digit growth Americas $253 m $249 m $126 m 40% of sales 40% of sales 2
Slide 89: Q1 2022: Strong profitability and free cash flow
Q1 2022: Strong profitability and free cash flow Adj. operating income Adj. EPS Operating cash flow (In $ millions) (In $ per share) (In $ millions) Targeted investments into key drivers ~65% of R&D spending focused on five pillars of growth $207 29 $232 Disciplined cost base $195 $0.80 Lower operat
Slide 90: Five pillars: QIAcuity digital PCR continuing to expand applications
Five pillars: QIAcuity digital PCR continuing to expand applications QIAcuity dPCR differentiation Easier Fully automated workflow in one compact instrument Faster Over twice as fast as droplet digital PCR; results in under 2 hours More versatile Scalable throughput and higher multiplexing capabilit
Slide 91: Five pillars: QIAstat-Dx menu driving installed base expansion
Five pillars: QIAstat-Dx menu driving installed base expansion Customer highlight Lancet Laboratories in Johannesburg, South Africa QIAstat-Dx allows them to handle more samples locally and immediately without batching or sending them to the main Johannesburg lab • First lab to detect Omicron COVID-
Slide 92: Core portfolios: Genomics key partnerships
Core portfolios: Genomics - adding value to NGS solutions through key partnerships New partnerships 2022 milestone >2.5 million clinical cases analyzed and interpreted using QIAGEN Digital Insights Validation of QIAGEN products Two-year licensing agreement on the Element AVITI Sequencer for QIAGEN D
Slide 93: Outlook: Q2 and FY 2022
Outlook: Q2 and FY 2022 Q2 2022 outlook FY 2022 outlook > $510 million CER ≥ $2.12 billion CER Net sales Adverse FX impact of ~ -4-5 p.p Adverse FX impact of ~ -4 p.p. Anticipated currency impact (Prior year: $567.2 m) (Prior year: $2,251.7 m) Non-COVID product groups Double-digit CER growth ≥ $0.46
Slide 94: Appendix
Appendix
Slide 95: Q2 and FY 2022: Outlook and assumptions
Q2 and FY 2022: Outlook and assumptions (As of April 26, 2022) Q2 2022 outlook FY 2022 outlook ≥ $510 million CER ≥ $2.12 billion CER Net sales (Prior year: $567.2 m) (Prior year: $2,251.7 m) Anticipated currency impact(1) Adverse impact of ~ -4-5 p.p. Adverse impact of ~ -4 p.p. > $0.46 CER > $2.14
Slide 96: Q1 2022: Consolidated Statements of Income
Q1 2022: Consolidated Statements of Income (unaudited) Three months ended Three months ended (In $ thousands, except share data) March 31, 2022 March 31, 2021 Net sales 628,391 567,206 Cost of sales: Cost of sales 198,118 178,974 Acquisition-related intangible amortization 15,303 17,641 Total cost o
Slide 97: 2022: Quarterly sales by product group
2022: Quarterly sales by product group (In $ millions at actual rates / Q1 2022 Q2 2022 Q3 2022 Q4 2022 FY 2022 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 265 17% 22% Diagnostic solutions(1) 174 16% 21% Of which QuantiF
Slide 98: 2021: Quarterly sales by product group
2021: Quarterly sales by product group (In $ millions at actual rates / Q1 2021 Q2 2021 Q3 2021 Q4 2021 FY 2021 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 227 47% 42% 203 1% -3% 202 -5% -6% 218 -7% -5% 851 6% 4% Diagnos
Slide 99: 2022: Sales by non-COVID and COVID-19 product groups
2022: Sales by non-COVID and COVID-19 product groups (In $ millions at actual rates / Q1 2022 Q2 2022 Q3 2022 Q4 2022 FY 2022 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Non-COVID product groups 400 10% 14% COVID-19 product groups 229 13% 1
Slide 100: 2021: Sales by non-COVID and COVID-19 product groups
2021: Sales by non-COVID and COVID-19 product groups Q1 2021 Q2 2021 Q3 2021 Q4 2021 FY 2021 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Non-COVID product groups 364 20% 16% 408 57% 52% 376 18% 17% 400 8% 10
Slide 101: 2022: Quarterly sales by product type, customer class and region
2022: Quarterly sales by product type, customer class and region (In $ millions at actual rates / Q1 2022 Q2 2022 Q3 2022 Q4 2022 FY 2022 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 561 13% 17% revenues
Slide 102: 2021: Quarterly sales by product type, customer class and region
2021: Quarterly sales by product type, customer class and region (In $ millions at actual rates / Q1 2021 Q2 2021 Q3 2021 Q4 2021 FY 2021 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 498 53% 48% 498 33% 2
Slide 103: Q1 2022: Reconciliation adjusted results
Q1 2022: Reconciliation adjusted results (unaudited) Net Gross Operating Pretax Income Tax Net Diluted (In $ millions, except EPS) sales profit income income tax rate income EPS First quarter 2022 Reported results 628.4 415.0 207.1 195.5 (40.2) 21% 155.3 0.67 Adjustments Business integration, acquis
Slide 104: Q1 2022: Footnotes for reconciliation adjusted results
Q1 2022: Footnotes for reconciliation adjusted results (unaudited) a) Results for 2022 include costs for acquisition projects, including continued integration activities at NeuMoDx, as well as costs and impairments related to our business in Russia. b) The decrease reflects the full amortization dur
Slide 105: 2022: Quarterly and full-year income statement summary
2022: Quarterly and full-year income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2022 Q2 2022 Q3 2022 Q4 2022 FY 2022 Net sales 628.4 Net sales (CER) 654.1 Gross profit 415.0 Gross profit margin 66.0% Adjusted gross profit 430.9 Adjusted gross profit margin 68
Slide 106: 2021: Quarterly and full-year income statement summary
2021: Quarterly and full-year income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2021 Q2 2021 Q3 2021 Q4 2021 FY 2021 Net sales 567.2 567.3 534.7 582.4 2,251.7 Gross profit 370.6 369.2 337.2 373.8 1,450.8 Gross profit margin 65.3% 65.1% 63.1% 64.2% 64.4% Adjus
Slide 107: Consolidated Balance Sheets
Consolidated Balance Sheets March 31, December 31, March 31, December 31, (In $ thousands, except par value) 2022 2021 (In $ thousands, except par value) 2022 2021 Assets (unaudited) Liabilities and Equity (unaudited) Cash and cash equivalents 770,515 880,516 Current portion of long-term debt 468,79
Slide 108: Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows (unaudited) Three months ended March 31, March 31, Three months ended March 31, March 31, (In $ thousands) 2022 2021 (In $ thousands) 2022 2021 Cash flows from operating activities: Cash flows from financing activities: Net income 155,312 129,223 Repayment of lo
Slide 109: Q1 2022: Currency impact
Q1 2022: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q1 2022 0 U.S. dollar 286.2 286.2 44% 0.0 Euro 166.4 178.7 27% 12.3 British pound 22.8 23.4 4% 0.6 Japanese yen 17.5 19.1 3% 1.7 Other currencies 135.5 146.7 22% 1
Slide 110: Employees as of March 31, 2022
Employees as of March 31, 2022 Europe / Middle Asia Pacific / Total Total Americas East / Africa Japan / ROW Q1 2022 Q4 2021 Change Production 416 1,241 155 1,812 1,818 0% R&D 211 731 55 997 992 1% Sales 578 864 812 2,254 2,237 1% Marketing 77 191 68 336 351 -4% Administration 79 393 159 631 630 0%
Slide 111: Your contacts
Your contacts Phoebe Loh Senior Director Calendar Global Investor Relations Annual General Meeting June 2022 Phone: +49 2103 29 11457 Mobile: +49 152 018 11457 Q2 2022 results July 2022 E-mail: phoebe.loh@qiagen.com Q3 2022 results November 2022 Alexandra Koenig Share information Coordinator Investo